Both in vivo and in vitro studies showed that hydrogen treatment could attenuate the stemness of glioma cells, which was evidenced by the decreased expression of stemness markers (CD133 and Nestin) and the enhanced expression of glia marker GFAP. This evidence concerns the gene PROM1 and central nervous system cancer.